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Dysfunction of the 140 aa protein -synuclein plays a central role in Lewy body disorders, including Parkinson’s disease, as well as in
multiple system atrophy. Here, we show that the expression of truncated human-synuclein(1–120), driven by the rat tyrosine hydrox-
ylase promoter on a mouse -synuclein null background, leads to the formation of pathological inclusions in the substantia nigra and
olfactory bulb and to a reduction in striatal dopamine levels. At the behavioral level, the transgenicmice showed a progressive reduction
in spontaneous locomotion and an increased response to amphetamine. These findings suggest that the C-terminal of-synuclein is an
important regulator of aggregation in vivo and will help to understand the mechanisms underlying the pathogenesis of Lewy body
disorders and multiple system atrophy.
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Introduction
Parkinson’s disease (PD) is the most common movement disor-
der. Neuropathologically, it is defined by nerve cell loss in several
brain regions, including the substantia nigra, and by the presence
of Lewy bodies and Lewy neurites (Goedert, 2001; Braak et al.,
2003). Abundant Lewy bodies and Lewy neurites in cerebral cor-
tex are also the defining neuropathological characteristics of de-
mentia with Lewy bodies (DLB), a common late-life dementia.
Ultrastructurally, Lewy bodies and Lewy neurites are composed
of filamentous and granular material (Forno, 1996). Missense
mutations (A30P, E46K, and A53T) and multiplications of the
-synuclein gene cause dominantly inherited forms of PD and
DLB (Polymeropoulos et al., 1997; Kru¨ger et al., 1998; Singleton
et al., 2003; Chartier-Harlin et al., 2004; Ibanez et al., 2004;
Zarranz et al., 2004), and -synuclein is the major component of
the filamentous inclusions of Lewy bodies and Lewy neurites
(Spillantini et al., 1997, 1998a). The correlation between Lewy
body formation and neurodegeneration suggests that the aggre-
gation of-synuclein is an important event during disease patho-
genesis. Therefore, dissection of the mechanisms underlying in-
clusion formation in vivo is essential for understanding disease
pathogenesis. In this respect, several mouse lines have been gen-
erated that express wild-type ormutant human-synuclein from
several different promoters (Kahle et al., 2000; Masliah et al.,
2000; van der Putten et al., 2000; Matsuoka et al., 2001; Rathke-
Hartlieb et al., 2001; Giasson et al., 2002; Lee et al., 2002; Neu-
mann et al., 2002; Richfield et al., 2002).
Overexpression ofwild-type human-synucleinwas found to
lead to the formation of granular deposits and subtle biochemical
abnormalities (Masliah et al., 2000). Subsequent work showed
that mice overexpressing A30P and A53T human -synuclein
developed accumulation of-synuclein in cell bodies and dystro-
phic neurites in several brain regions (van der Putten et al., 2000;
Giasson et al., 2002; Lee et al., 2002; Neumann et al., 2002), with
one study (Giasson et al., 2002) documenting the presence of
filamentous -synuclein deposits in cerebellum and spinal cord.
However, none of these studies, which used either the Thy1 or the
prion protein promoter, resulted in the accumulation of
-synuclein in dopaminergic nerve cells of the substantia nigra.
Furthermore, expression of wild-type or mutant human
-synuclein from the tyrosine hydroxylase (TH) promoter did
not result in the formation of pathological inclusions (Matsuoka
et al., 2001; Rathke-Hartlieb et al., 2001; Richfield et al., 2002).
Received June 3, 2005; revised Feb. 28, 2006; accepted March 3, 2006.
Thisworkwas supported by theUnited KingdomAlzheimer’s Research Trust, the Parkinson’s Disease Society, the
Biotechnology and Biological Sciences Research Council, and theMedical Research Council. G.K.T. was supported by
an Overseas Research Scholarship award, a Trinity College Scholarship, and the MB/PhD program of Cambridge
University. P.G.R. has a studentship from European Union Marie Curie Actions RTN-NSR number 504636. B.G. was
supported by United States Public Health Service Grant P30 AG10133. S.L.L. is the recipient of an Alzheimer’s
Research Trust fellowship.We thankB. Allen andR. Raha-Chowdhury for help, H. vander Putten for the THpromoter
construct, and V.M.-Y. Lee for antibody Syn h119.
Correspondence shouldbeaddressed toMariaGrazia Spillantini at theaboveaddress. E-mail:mgs11@cam.ac.uk.
DOI:10.1523/JNEUROSCI.4965-05.2006
Copyright © 2006 Society for Neuroscience 0270-6474/06/263942-09$15.00/0
3942 • The Journal of Neuroscience, April 12, 2006 • 26(15):3942–3950
Previous work has shown that Lewy body extracts are en-
riched in C-terminally truncated -synuclein (Baba et al., 1998;
Tofaris et al., 2003) and that human -synuclein lacking the
C-terminal 20 amino acids [-synuclein(1–120) (-Syn120)] as-
sembles into filaments in vitro faster than either wild-type or
mutant protein (Crowther et al., 1998; Serpell et al., 2000;Murray
et al., 2003). It is therefore possible that truncation of-synuclein
could accelerate aggregation in a similarmanner in vivo, resulting
in neuropathological changes at an earlier age. Here, we investi-
gated the effects of this modification by generating transgenic
mice expressing human -Syn120 from the rat TH promoter.
Materials andMethods
Generation of transgenic mouse lines. Transgene constructs were gener-
ated using the rat THpromoter (see Fig. 1A). The TH cassette (a kind gift
from Dr. H. van der Putten, Novartis, Basel, Switzerland) (Min et al.,
1994) directs high expression in dopaminergic and other TH-positive
neurons. Human -synuclein(1–120) DNA was generated from the
wild-type cDNA (Jakes et al., 1994) by PCR amplification, and a Kozak
consensus sequence was introduced upstream of the initiation codon.
The expression construct was generated by subcloning human
-synuclein(1–120) DNA into the unique EcoRI site of the expression
vector. Before microinjection, vector sequences were removed by diges-
tion withNotI. Founders and transgenic progeny were identified by PCR
analysis of lysates from tail biopsies using two sets of primers. Transgenic
lines were established as C57BL/6J CBA/ca hybrids and subsequently
backcrossed to C57BL/6J, which lacks -synuclein (Specht and Scho-
epfer, 2001).
Immunoblotting. Total protein concentrations in tissue lysates were
measured using the biocinchoninic acid assay (BCA; Pierce, Rockford,
IL), and equal amountswere run on 12 or 15%SDS-PAGE. Proteinswere
transferred electrophoretically onto nitrocellulose membranes (Milli-
pore, Bedford, MA). The membranes were blocked with 4% milk and
incubated with the appropriate primary antibodies. Bound antibodies
were then visualized using peroxidase-conjugated secondary antisera (1:
2000) and enhanced chemiluminescence (PerkinElmer Life Sciences,
Boston, MA).
Immunohistochemistry. Mice were anesthetized with an intraperito-
neal injection of xylazine and ketamine or pentabarbitone, followed by
intracardial perfusion with TBS and 4% ice-cold (w/v) paraformalde-
hyde. The brain was dissected and postfixed in 4% paraformaldehyde
before being transferred to a 30% sucrose solution. Sections (15 or 30
m) were cut on a freezing microtome, and immunohistochemistry was
performed on free-floating sections. Incubations were done in TBS con-
taining 0.25% Tween 20, and the sections were quenched for 20 min in
20% methanol/1.5% H2O2. When rabbit antisera were used, sections
were preincubated with 3% goat serum for 1 h and incubated with pri-
mary antibody overnight at room temperature in 1% goat serum, fol-
lowed by incubation with biotinylated goat anti-rabbit antibody (1:200;
Vector Laboratories, Burlingame, CA) in 1% goat serum for 1 h and
avidin–biotin peroxidase complex for 30 min (ABC Elite; Vector Labo-
ratories). Staining was visualized using 3,3-diaminobenzidine (DAB;
Sigma, St. Louis, MO) as the chromogen. When monoclonal antibodies
were used, sections were processed as above, except that biotinylated
horse anti-mouse secondary antibody and the mouse-on-mouse kit
(Vector Laboratories) were used to minimize background staining. For
double-immunofluorescence analysis of -synuclein, TH, and CD11b,
Alexa Fluor 488-conjugated (green) and Alexa Fluor 594-conjugated
(red) secondary antibodies (Invitrogen, Eugene, OR) were used, and the
sections were mounted using a glycerol-based anti-fading kit (Invitro-
gen). A panel of anti--synuclein antibodies was used. Antiserum PER4
recognizes the C-terminal region of -synuclein (Spillantini et al.,
1998a), whereas antiserum PER7was raised against recombinant human
-synuclein(1–120) (Jakes et al., 1999). They recognize mouse and hu-
man -synucleins. Syn-1 (Transduction Laboratories, Lexington, KY)
and LB509 (Zymed, San Francisco, CA) are monoclonal antibodies,
which recognize residues 91–99 and 115–122 of human -synuclein,
respectively (Jakes et al., 1999; Perrin et al., 2003). Syn-1 recognizes both
mouse andhuman-synucleins, whereas LB509 is specific for the human
protein. Antibody Syn h119 (a kind gift fromDr. V.M.-Y. Lee, University
of Pennsylvania, Philadelphia, PA) is a monoclonal antibody specific for
residues 71–82 of -synuclein, which recognizes the mouse and human
proteins (Mishizen-Eberz et al., 2003). Syn204 (Biomeda, Foster City,
CA) is a human-specific monoclonal antibody against the amino termi-
nus of -synuclein (Giasson et al., 2000). Monoclonal anti-TH antibody
was purchased from Chemicon (Temecula, CA). Monoclonal anti-
CD11b was purchased from Serotec (Oxford, UK). SMI-31 (Sternberger
Monoclonals, Lutherville,MD) is amonoclonal antibody that recognizes
phosphorylated neurofilaments.
Thioflavin S staining. Fixed mouse brain sections (15 m) were incu-
batedwith 1% thioflavin S (Sigma) for 10min andwashed sequentially in
70% and 50% ethanol (4 min each), followed by a 3 min wash in water.
Sections were left to dry for 20 min in the dark, before being mounted in
glycerol-based anti-fading kit (Invitrogen) containing 1 ng/l 4,6-
diamidino-2-phenylindole dihydrochloride (DAPI).
Electron microscopy. Mice were anesthetized with an intraperitoneal
injection of xylazine and ketamine and perfused intracardially with PBS,
followed by 4% cold paraformaldehyde and 0.25% glutaraldehyde. The
brain was dissected and postfixed in the same solution for another 2 h.
For immunoelectronmicroscopy, fixed specimens (1mm3)werewashed
in distilled water and placed in TBS, pH 7.6. Sections (50m thick) were
cut using a vibratome. Immunogold labeling with antibody Syn-1 (1:
100) was performed using 10 nm gold particles (Goldmark Biologicals,
Phillipsburg, NJ) conjugated to goat anti-mouse IgG (diluted 1:10). Sec-
tions were postfixed in 2.5% glutaraldehyde, followed by 1% osmium
tetroxide, dehydrated through a graded alcohol series, and embedded in
epoxy resin. Semithin sections were stained with toluidine blue. Ultra-
thin sections were contrasted with lead citrate and uranyl acetate and
scanned with electron microscopy.
Sequential extraction of-synuclein.Extraction of-synucleinwas per-
formed as described previously (Tofaris et al., 2003). Tissues were ho-
mogenized on ice in 5 vol of TBS [50 mM Tris-HCl, pH 7.4, 175 mM
NaCl, 5 mM EDTA, 0.1 mM PMSF, 1 mM N-ethyl-maleimide, plus com-
plete proteasome inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany)] and spun for 30 min at 120,000  g at 4°C. The resulting
supernatants corresponded to the TBS soluble fraction. The pellets
were homogenized in TBS containing 1% Triton X-100, followed by
centrifugation. The pellets were in turn homogenized in TBS contain-
ing 1 M sucrose, and, after centrifugation, floating myelin was discarded.
The resulting pellets were extracted with radioimmunoprecipitation as-
say (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 175 mM NaCl, 5 mM EDTA,
1% NP-40, and 0.5% sodium deoxycholate) and 0.1% SDS, followed by
centrifugation. The detergent-insoluble pellets were solubilized in 8 M
urea/5% SDS. In some experiments, the 1%Triton step was omitted, and
TBS extraction was directly followed by RIPA buffer treatment.
HPLC. Striatal monoamine levels were compared between transgenic
and littermate control mice at 1, 3, 6, 9, and 12 months of age. The
anterior striatum was dissected on ice, weighed, and homogenized in 0.1
M cold perchloric acid. Homogenates were centrifuged twice at 15,000
rpm for 5 min at 4°C, and the supernatants were diluted 1:10 in 0.1 M
perchloric acid.Theywere storedat80°Cfor2d.Onthedayofanalysis, the
supernatants were thawed andmixedwith 3,4-dihydroxybenzylamine as an
internal standard. Levels of dopamine, homovanillic acid, and
5-hydroxytryptamine (5-HT) were determined by HPLC combined with
electrochemical detection, as described previously (O’Connell et al., 1991).
Behavioral testing. Twenty-three -Syn120 transgenic and 25 wild-
type control mice were assessed for spontaneous locomotor activity
(LMA) and the effectiveness of D-amphetamine sulfate tomodulate LMA
at 6 and 18 months of age (n 12 and 13 for wild-type mice at 6 and 18
months of age and n 12 and 11 for transgenic mice at 6 and 18months
of age, respectively). Mice were individually placed into test chambers
[for a description of the apparatus, see Isles et al. (2004)] for 30 min
before administration of 1 mg/kg (i.p.) D-amphetamine sulfate or 0.7%
saline vehicle and LMA, and then recorded for an additional 120 min.
The mice were given two sessions, 7 d apart, and drug treatments were
counterbalanced across groups and ages. All procedures were conducted
in accordance with the requirements of the United Kingdom Animals
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(Scientific Procedures) Act 1986 (behavioral
testing). Spontaneous LMA, designated as the
total number of beam breaks made during the
30 min preinjection phase from the first LMA
session was analyzed by two-way ANOVA with
the factors GENOTYPE (control, transgenic)
and AGE (6 and 18months) and habituation to
the chambers, examined by dividing the data
into 5 min time bins, by three-way ANOVA
with factors GENOTYPE, AGE, and repeated
measure of TIME (six 5 min time bins). Total
activity after drug treatment was subjected to a
three-way ANOVA with factors GENOTYPE,
AGE, and TREATMENT (vehicle, amphet-
amine). The percentage increase in LMA for
each 30min block after drug treatment was cal-
culated relative to the LMA in the final 10 min
of the preceding 30 min habituation session.
These data were analyzed by four-way ANOVA
with factorsGENOTYPE,AGE,TREATMENT,
and repeated measure of TIME (four 30 min
time bins).
Results
Expression of human -Syn120
Five founders were obtained, three of
which transmitted the transgene in aMen-
delian manner. By immunoblotting using
antibody Syn-1, two lines expressed high
levels of -Syn120 in the nigrostriatal
pathway and the olfactory bulb, brain re-
gions expressing high levels of TH. One of
these lines was used for additional charac-
terization (Fig. 1B). Relative to immuno-
reactivity for TH, the expression of
-Syn120 was higher in the olfactory bulb
than in the substantia nigra, and high lev-
els of expression were detected in both re-
gions at all ages examined (Fig. 1D,E).
When compared with the substantia nigra
and the olfactory bulb of wild-type
C57BL/6 mice with endogenous
-synuclein, transgenic -Syn120 was
present at lower levels than the endoge-
nous protein (Fig. 1C). However, it has to
be considered that althoughmost neurons
in the wild-type mouse express
-synuclein, transgenic -Syn120 is only
expressed in TH neurons. Antibodies
PER4 and LB509, which are specific for
the last 20 amino acids of -synuclein
(Jakes et al., 1999), failed to recognize the
transgenic protein. As expected (Specht
and Schoepfer, 2001), no mouse -synuclein was detected in
either transgenic lines or littermate controls.Heterozygous trans-
genic mice were used for this study.
Immunohistochemical distribution of human -Syn120
The cellular localization of -Syn120 was studied by single- and
double-labeling immunohistochemistry. Strong immunoreac-
tivity was present in the somatodendritic compartment of the
vast majority of TH-positive neurons from 6 weeks of age on-
wards. Within the nigrostriatal pathway of young mice, staining
for -Syn120 closely followed TH staining throughout the cell
soma and around the nucleus, extending into dendritic processes
(Fig. 2). Colocalization of the two proteins was observed in 90%
of cells. -Syn120 was also present in the corresponding terminal
fields, as indicated by punctate staining in the striatum (Fig. 3a).
However, when stained with an antibody against TH, axons of
transgenicmice appearedwith focal varicose swellings in contrast
to littermate controls. Using antiphosphorylated neurofilament
antibodies, axons appeared to have a larger diameter in trans-
genic mice (Fig. 3b,c,h–j). In the olfactory bulb, in contrast,
-Syn120 accumulated in inclusion-like structures at all ages ex-
amined (Fig. 3d,f). As a result, its staining pattern did not com-
pletely overlap with the more diffuse distribution of TH (Fig. 3e)
and was different from the staining observed with the same anti-
Figure 1. Expression of-Syn120 in transgenic mouse brain. A, Schematic diagram of the construct: human-synuclein(1–
120) DNA was cloned downstream of the rat TH promoter. B, Immunoblot probed for-synuclein (antibody Syn-1) and TH. The
tissues were obtained from 6-week-old transgenicmice and littermate controls. Cx, Cerebral cortex; Cb, cerebellum; OB, olfactory
bulb; SN, substantia nigra. No endogenous-synucleinwas detected at 19 kDa. C, Expression levels of-Syn120 in olfactory bulb
of transgenic mice compared with full-length-synuclein in olfactory bulb from C57BL/6 mice. D, E, Immunoblotting (antibody
Syn-1) of extracts from olfactory bulb (D) and substantia nigra (E) at 6, 12, and 24 months showed stable expression of the
transgene. rS, Recombinant full-length human-synuclein.
Figure 2. Cellular localization of-Syn120 in the substantia nigra of transgenic mice. a–d, Adjacent coronal sections of the
substantia nigra from 6-month-old transgenic (a, b) and littermate control (c, d) mice were stained for TH and -synuclein
(Syn-1). TH-positive neurons from transgenicmice (a) showed somal expression of-Syn120 (b). A similar region from littermate
control mice was positive for TH (c) but negative for -synuclein (d), as would be expected in mice with a null -synuclein
background. e, f, Immunofluorescence microscopy of the substantia nigra using anti-TH (e, red) and anti--synuclein (f, green)
antibodies showed colocalization (g, yellow). Scale bar: (in a) a–d, 200m; e–g, 250m.
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-synuclein antibody in C57BL/6 control mice expressing the
endogenous protein (Fig. 3g). TH-positive neurons in the locus
ceruleus were also immunoreactive for -Syn120 (data not
shown).
Staining for human-Syn120 in substantia nigra as a
function of age
Transgenic mice were studied at 3, 6, and 12–14 months of age
(n 3 per time point). At 3months (Fig. 4a),-Syn120 accumu-
lated in the somatodendritic compartment, where its staining
pattern resembled that of TH. By 12–14months of age, patholog-
ical changes were detected (Fig. 4b–j). They included dense,
shrunken perikarya (Fig. 4b), beaded or dystrophic processes
(Fig. 4c,e), as well as inclusions that were either perinuclear (Fig.
4d,j, arrows) or very localized (Fig. 4f,g, arrowheads). Double
immunostaining for both TH and
-synuclein confirmed the localization of
dense inclusions within the cytoplasm of
dopaminergic neurons (Fig. 4g). Granular
deposits and vacuolation of the cytoplasm
were also detected in older mice (Fig. 4h–
j). Furthermore, there was an increase in
microglial cells associated with affected
brain regions, indicative of an inflamma-
tory response (Fig. 5A,B). There was no
significant cell loss by cell counting of TH-
positive neurons in the substantia nigra
using stereology (data not shown). Stain-
ing was observed with -synuclein anti-
bodies Syn-1, Syn h119, andPER7, but not
with PER4 or LB509. Inclusions were not
stained with anti-neurofilament or anti-
ubiquitin antibodies (data not shown).
Electron microscopy
Pathological profiles were investigated by
electron microscopy and immunogold la-
beling of olfactory bulb using antibody
Syn-1. The -Syn120 aggregates had a
mixed granular and fibrillar morphology
(Fig. 6a). A subset of inclusions in olfac-
tory bulb and substantia nigra was thiofla-
vin S-positive, consistent with the electron
microscopic findings (Fig. 6b,c). Occa-
sional inclusions were present in
3-month-old mice, and their numbers in-
creased with age.
Sequential extraction of
human -Syn120
-Synuclein was sequentially extracted
from olfactory bulb and substantia nigra
of 6-month-old transgenic mice using
TBS, 1%Triton X-100, RIPA buffer, and 8
M urea/5% SDS (Fig. 7). A protein band
with an apparent molecular mass of 12
kDa was detected with antibody Syn-1 in
theTBS andTritonX-100 fractions. It cor-
responds to monomeric -Syn120. When
the RIPA-insoluble material was treated
with urea, in addition to a high-molecular
weight smear, a band corresponding to
monomeric truncated -Syn120 was
found in substantia nigra and olfactory bulb. The smear and the
monomeric -Syn120 band present in the urea fraction were
stained by antibodies Syn-1, Syn204, and PER 7 (Fig. 7). The
substantia nigra from a case of PD was extracted in parallel and
the urea-soluble material is shown (Fig. 7). In control experi-
ments, full-length -synuclein extracted from age-matched
C57BL/6 mice with endogenous protein was detected in the sol-
uble, but not the urea fraction (Fig. 7). Furthermore, no staining
was detected in the soluble or urea-treated extracts from litter-
mate controls (data not shown).
Neurochemical changes
The impact of human-Syn120 expression on dopamine synthe-
sis and turnover was assessed in the anterior striatum of trans-
genic mice at 1, 3, 6, 9, and 12 months of age (n 4 per group).
Figure 3. Histological characterization of-Syn120 in the striatum and the olfactory bulb. a, Punctate neuropil localization of
-Syn120 in the striatumwas consistentwith enrichment at synaptic nerve terminals.b, c, TH staining showedenlargednerve cell
processes in striatumof transgenic (b) but not in littermate control (c)mice.h–j, Abnormal axonalmorphologywas confirmed by
phosphorylated neurofilament staining with SMI 31 antibody in transgenic (h, i) compared with littermate control (j) mice.
-Syn120 immunoreactivity (syn-1 antibody) in the olfactory bulb (d) from a transgenic mouse. e, At a higher magnification, TH
staining appeared diffusely distributed along the somatodendritic compartment. Abundant-Syn120-syn-1-positive inclusions
(f ) were present in the olfactory bulb at all ages examined, showing a different distribution of the protein compared with
endogenous full-length-synuclein in C57BL/6 mice stained with the same antibody (g). Scale bars: a, d, 600m; (in h) h–j, 5
m; (in g) b, c, e, f, 150m.
Tofaris et al. •Mice Transgenic for Human-Synuclein(1–120) J. Neurosci., April 12, 2006 • 26(15):3942–3950 • 3945
When compared with age-matched litter-
mate controls, although striatal dopamine
levels were the same at 1 month, a statisti-
cally significant 30% reduction ( p 
0.0001,F 32.8,R2 0.653)was detected
at later time points in the transgenic mice
(Fig. 8). This was paralleled by a 30% re-
duction in the dopamine metabolite ho-
movanillic acid (Fig. 8). Measurement of
5-HT levels showed no significant differ-
ence between transgenic and littermate
control mice (Fig. 8).
Spontaneous locomotor activity
The effect of -Syn120 expression on
spontaneous activity of 6- and 18-month-
old transgenicmice is shown in Figure 9,A
and B. At 6 months, there was no signifi-
cant difference in total activity between
wild-type and transgenic mice, whereas at
18 months, transgenic mice made signifi-
cantly fewer beam breaks during the 30
min test than age-matched controls
(AGE  GENOTYPE interaction, F(1,44)
 6.6, p 0.02); this was observed against a general reduction in
locomotor activity by the older group of mice (effect of AGE,
F(1,44)  15.2, p  0.001). The pattern of reduced activity in
18-month-old transgenic mice was consistent throughout the
session [Fig. 9B, no AGE  TIME  GENOTYPE interaction,
F(5,220)  0.3, not significant (n.s.)]. However, all mice showed
equivalent levels of habituation to the environment (effect of
TIME, F(5,220) 28.8, p 0.001), and the older mice made con-
sistently fewer beambreaks in each 5min time bin (AGETIME
interaction, F(5,220) 5.9, p 0.001).
Effects of amphetamine
After the 30 min habituation sessions, control and -Syn120
transgenic mice were given an injection of either saline vehicle or
amphetamine (Fig. 9C). When the drug treatment effects were
calculated as a percentage of the final 10 min of the preinjection
habituation session, 18-month-old transgenic mice exhibited an
enhanced response to amphetamine relative to age-matched con-
trols and 6-month-old transgenic mice and controls (effect of
AGE  TREATMENT  GENOTYPE, F(1,88)  6.8, p  0.02).
Overall, amphetamine yielded a significant increase in locomotor
activity (effect of TREATMENT, F(1,88)  58.3, p  0.001) that
peaked 60min after administration (TIMEDRUG interaction,
F(3,264)  15.3, p  0.001). There were no genotype-related dif-
ferences in the total number of beam breaks made in the 2 h after
drug or vehicle injection (data not shown, effect of GENOTYPE,
F(1,88)  1.8, n.s.), although 18-month-old mice made signifi-
cantly fewer beam breaks than 6-month-old mice (effect of AGE,
F(1,88)  12.5, p  0.001). There was no interaction between
genotype, age, and drug treatment (F(1,88) 0.1, n.s.).
Discussion
-Synuclein is a presynaptic protein, which gives a characteristic
punctate staining in rodent and human brain (Jakes et al., 1994).
Similar findings were obtained for -Syn120 in the striatum and
olfactory bulb, indicating that it was transported like the full-
length protein. However, the progressive accumulation of
-Syn120 in the somatodendritic compartment was pathological
and associated with the accumulation of microglia and inflam-
mation. In 3-month-old transgenic mice, -synuclein showed a
diffuse somatodendritic distribution; by 12–14 months,
perikarya in the substantia nigra were shrunken or contained
cytoplasmic inclusions, and axons in the striatum contained var-
icose swellings and had an enlarged diameter, resembling the
pathological profiles in PD (Duda et al., 2002; Neumann et al.,
2004).
In the olfactory bulb, -Syn120-positive inclusions were al-
ready present by 3 months of age. This is reminiscent of human
brain, where Lewy bodies and Lewy neurites appear in the olfac-
tory bulb before the substantia nigra (Braak et al., 2003). Olfac-
tory dysfunction precedes clinical motor signs in PD (Katzen-
schlager and Lees, 2004). Electron microscopy and immunogold
labeling of -Syn120 deposits revealed the presence of granular
and fibrillar structures in the olfactory bulb. Furthermore, some
inclusions in substantia nigra and olfactory bulb were thioflavin
S-positive, consistent with the presence of aggregated -Syn120.
By sequential extraction, we detected insoluble -Syn120 aggre-
gates in the olfactory bulb and the substantia nigra of transgenic
mice. Their limited solubility was similar to that of -synuclein
extracted fromPDandDLBbrains (Campbell et al., 2000; Tofaris
et al., 2003), although there was less insolublematerial than in the
human conditions. Furthermore, although in other reports the
insoluble material appeared as a smear containing distinct bands
as well as monomeric -synuclein (Kahle et al., 2001), this was
not the case here, where only one band corresponding to mono-
Figure 4. Histological characterization of -Syn120 in the substantia nigra. a, At 3 months of age, -Syn120 was diffusely
distributed through the somatodendritic compartment. b, At 14 months,-Syn120 immunoreactivity revealed the presence of
pyknotic perikarya. c, e, Between 11 and 14months, a number of pathological profileswas observed,which included beaded (c) or
swollen (e) processes. Perinuclear aggregates (d and j, arrows) or dense inclusions (f, arrowheads) within TH neurons (g, arrow-
head, double-stained neurons with anti-TH blue and Syn1 brown) are shown. Vacuolation of the cytoplasm (arrows h, i) was
evident at this stage (h–j). The following-synuclein antibodieswere used: Syn-1,a,b, e–i; PER7, c,d; SYNh119, j. Scale bar, 60m.
Figure 5. Microglial activation. Double-staining immunofluorescence with TH (red) and
CD11b (green) shows increased microglial cell numbers in the SN of transgenic mice (A) com-
pared with littermate controls (B).
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meric -Syn 120 was present in the insoluble fraction. This dif-
ference could be attributable to the different methods of extrac-
tion, the nature of the transgenic protein (truncated versus full-
length) or the amount of insoluble aggregates and their
distribution, which was limited to substantia nigra and olfactory
bulb in the -Syn120 transgenic mice (Kahle et al., 2001; Giasson
et al., 2002). The -Syn120 inclusions were usually ubiquitin
negative, consistent with the extensive evidence indicating that
the ubiquitination of -synuclein in Lewy bodies and Lewy neu-
rites is a late event (Spillantini et al., 1998a; Tofaris et al., 2001,
Sampathu et al., 2003; Tofaris et al., 2003). To our knowledge,
this is the first transgenic mouse model with mixed filamentous
and granular-synuclein aggregates in dopaminergic neurons. It
shows that truncated human protein expressed on a -synuclein
null background can induce inclusion formation in vivo.
The neurochemical effects of human -Syn120 expression in
the striatum were assessed in mice up to 12 months of age. Al-
though at 1 month there was no difference in dopamine levels
between transgenic mice and littermate controls, a significant
reduction in dopamine and homovanillic acid, but not 5-HT,was
detected from 3 months onwards. These findings indicate a spe-
cific dysfunction of the dopaminergic system, in agreement with
the differential expression of -Syn120, and are consistent with
Figure6. Ultrastructure of-Syn120 aggregates.a, Immunoelectronmicroscopy (antibody
Syn-1) of the olfactory bulb from 7-month-old transgenic mice revealed granular and filamen-
tous deposits. Arrows point to filamentous structures.b, c, Thioflavin S fluorescence in olfactory
bulb (b) and substantia nigra (c). Nuclei were visualized with DAPI (blue fluorescence). Scale
bar: a, 250 nm.
Figure 7. Sequential extraction of-Syn120 from substantia nigra and olfactory bulb. Sub-
stantia nigra and olfactory bulb tissues from 6-month-old transgenic mice were sequentially
extracted with Tris-HCl, Triton X-100, RIPA buffer, and urea, followed by immunoblotting with
antibodies Syn-1 (a– c), Syn204 (d), and PER7 (e). a, The urea-soluble material from the sub-
stantia nigra of a PD patient was used as a positive control. In age-matched C57BL/6 wild-type
mice with endogenous-synuclein, the protein was detected only in soluble fractions (c) but
not in urea extracts (U in c, CU in d, e). CU, Urea extract from control wild-type mice with
endogenous-synuclein. The asterisk indicates the position of themonomeric-Syn120 band
in the urea-soluble fractions. SN, Substantia nigra; U, urea; T, Tris-HCl; R, RIPA buffer; T/T, Triton
X-100; OB, olfactory bulb.
Figure8. Striatal dopamine (DA), homovanillic acid (HVA), and5-HT levels in transgenic and
littermate control mice at different ages. Top panel, A significant reduction ( p 0.0001) in
striatal dopamine levels was present in transgenicmice at 3, 6, 9, and 12months of age but not
in 1-month-old animals. Middle panel, This was paralleled by a similar reduction ( p 0.003)
in the levels of homovanillic acid. Bottom panel, Striatal 5-HT levels did not differ significantly
between control and transgenic mice. Error bars represent SEM.
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neurochemical changes in PD, which is characterized by a defi-
ciency in striatal dopamine and homovanillic acid (Hornyk-
iewicz, 1998). Unlike in PD, there was no evidence of significant
nerve cell death in our model. It is conceivable that the reduction
in dopamine levels is best explained by a metabolic dysfunction
resulting from the early accumulation of-Syn120 in presynaptic
nerve terminals in the striatum rather than by changes at the cell
body level in the substantia nigra. In support of the latter is the
temporal correlation between the presence of dilated striatal ter-
minals and dopamine deficiency and the evidence from studies in
human brain, which showed that, in PD, although striatal dopa-
mine is decreased by 80%, nigral neurons are only reduced by
50% (Hornykiewicz, 1998).
The behavioral analysis, which revealed a progressive reduc-
tion in spontaneous locomotor activity and an increased re-
sponse to amphetamine, was consistent with transgene-induced
effects on dopamine-mediated functions. Similar findings have
previously been reported in animal models of PD after chemical
and genetic lesions, which reduce presynaptic dopamine (Cai et
al., 2002; Marazziti et al., 2004). Furthermore, expression of full-
length mutant, but not wild-type, -synuclein under the control
of the TH promoter led to a significant decrease in locomotor
activity with aging (Thiruchelvam et al., 2004), suggesting that
C-terminal truncation of the protein can have a pathological phe-
notype similar to that of a disease-causing missense mutation.
The enhanced response to amphetamine is reminiscent of dopa-
mine “supersensitivity,” a postsynaptic adaptation related to the
chronic lowering of basal dopamine levels in terminal regions,
especially the striatum. The synapticmechanisms underlying this
phenomenon can involve increased dopamine receptor numbers
or be related to changes in binding efficiencies and/or down-
stream signal transduction pathways (Cai et al., 2002; Gerfen et
al., 2002). Although several other transgenic mouse models of
-synuclein expression have been produced, they showed accu-
mulation of -synuclein in brain regions other than the substan-
tia nigra (Giasson al., 2002), or the inclusions were granular and
nuclear (Masliah et al., 2000), or there were no inclusions
(Thiruchelvam et al., 2004). Ourmodel is the first to demonstrate
a direct link between granular and filamentous -synuclein cyto-
plasmic pathology confined to the dopaminergic system and a
progressive behavioral deficit without involvement of areas of
motor function (i.e., corticospinal tract and anterior horn cells),
which were affected in othermodels (Masliah et al., 2000; van der
Putten et al., 2000; Giasson et al., 2002; Neumann et al., 2002).
These data, together with our immunohistochemical and neuro-
chemical findings, raise the possibility that behavioral deficits
may predate overt neurodegeneration and point to nerve termi-
nals as possible anatomical substrates for the primary insult in
-synucleinopathies.
The above findings show that mice expressing human
-Syn120 in dopaminergic neurons recapitulate many changes
characteristic of human Lewy body diseases. The major limita-
tions of our model are the small number of fibrils, the absence of
significant cell death, and the lack of endogenous full-length
-synuclein. One of our aims was to produce a model whereby
the effect of aggregated human-synuclein could be investigated
without interference from endogenous mouse protein. A previ-
ous in vitro study has reported that the fibrillization of human
-synuclein is inhibited in the presence of the mouse protein
(Rochet et al., 2000). However, truncated human -synuclein
can cross-seed the fibrillation of full-length protein in vitro (Mur-
ray et al., 2003). It will therefore be important to determine
whether the presence of full-length protein influences the patho-
logical and behavioral phenotype detected in -Syn120 mice.
C-terminal truncation of -synuclein is considered by some
to play a role in the pathogenesis of Lewy body diseases and the
degeneration of dopaminergic nerve cells (Tofaris et al., 2003; Li
et al., 2005; Liu et al., 2005). C-terminally truncated -synuclein
forms filaments at a faster rate than the full-length protein
(Crowther et al., 1998; Serpell et al., 2000; Murray et al., 2003).
Furthermore, C-terminally truncated -synuclein has been de-
tected in Lewy bodies in human diseases and in the brains of
transgenic mice expressing mutant human -synuclein (Giasson
et al., 2002; Lee et al., 2002; Tofaris et al., 2003). How truncated
-synuclein can be generated in cells, under pathological condi-
tions, is currently unclear; the proteasome could be involved (To-
faris et al., 2001; Liu et al., 2003). Isolated -synuclein filaments
fromhuman brain aremade of the full-length protein, suggesting
that truncation may occur after assembly (Spillantini et al.,
1998a,b; Crowther et al., 2000; Takao et al., 2004). This notwith-
standing, it is clear that the C-terminal region of -synuclein,
which binds dopamine derivatives (Norris et al., 2005), is a neg-
ative regulator of self-assembly. Therefore, modifications in this
region, such as oxidation, nitration, and phosphorylation
(Hashimoto et al., 1999; Giasson et al., 2000; Fujiwara et al.,
2002), may well influence the propensity of-synuclein to aggre-
gate in vivo in a way similar to truncation. The same is true of
molecules that bind to themonomeric protein. Thus, polyamines
have been shown to promote the aggregation of -synuclein
through binding to its C-terminal region (Antony et al., 2003;
Fernandez et al., 2004). Other positively charged molecules may
act in a similar way (Goers et al., 2003).
In conclusion, the present work describes the production and
characterization of a novel transgenic mouse model for
-synuclein aggregation. Expression of human -Syn120 under
the control of the TH promoter led to the formation of patholog-
Figure 9. Spontaneous and amphetamine-induced activity in 6- and 18-month-old
-Syn120 transgenic and control mice. A, Eighteen-month-old transgenic mice showed re-
duced levels of spontaneous activity,measured as infrared beambreaks, comparedwith equiv-
alent agedwild-typemice, and, overall, the oldermice showed a reduction in activity relative to
6month-old subjects.B,When examined inmore detail, all of the groups ofmice habituated to
the environment equally during the 30min test. After 30min habituation, mice received injec-
tions of either saline vehicle or 1 mg/kg D-amphetamine intraperitoneally, counterbalanced
over two sessions 7 d apart, and activity was monitored for an additional 120 min. Amphet-
amine induced increasedactivity in allmice,withapeak response60minafter injection (n11
and 13 for 6-month-old, and n 12 and 12 for 18-month-old transgenic and control mice,
respectively).C, Comparedwithwild-typemice at both ages and6-month-old-Syn120 trans-
genic mice, 18-month-old-Syn120 mice exhibited a significantly enhanced response to am-
phetamine relative to the preinjection activity performance.
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ical inclusions in substantia nigra and olfactory bulb, as revealed
by morphological and biochemical studies. This was accompa-
nied by a reduction in dopamine levels in the striatum, a progres-
sive reduction in spontaneous locomotor activity, and an in-
creased response to amphetamine. Our findings suggest that the
C-terminal region of -synuclein is an important regulator of
aggregation.
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